Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells (STOPCAP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Arshed A. Quyyumi, Emory University
ClinicalTrials.gov Identifier:
NCT00166036
First received: September 12, 2005
Last updated: August 28, 2014
Last verified: August 2014
Results First Received: June 8, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Diabetes Mellitus
Metabolic Syndrome X
Hypercholesterolemia
Interventions: Drug: Atorvastatin
Drug: Pravastatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Previous statin or other lipid lowering medications will be discontinued for 2 months. Subjects will be on stable medical therapy for at least 2 months before recruitment.

Reporting Groups
  Description
Atorvastatin 10 mg Once Daily for 12 Weeks
Pravastatin 80 mg Once Daily for 12 Weeks

Participant Flow:   Overall Study
    Atorvastatin 10 mg     Pravastatin 80 mg  
STARTED     17     19  
COMPLETED     17     19  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Atorvastatin 10 mg Subject treated with oral Atorvastatin 10 mg for 12 Weeks.
Pravastatin 80 mg Subject treated with oral Pravastatin 80 mg for 12 Weeks.
Total Total of all reporting groups

Baseline Measures
    Atorvastatin 10 mg     Pravastatin 80 mg     Total  
Number of Participants  
[units: participants]
  17     19     36  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     16     18     34  
>=65 years     1     1     2  
Age  
[units: years]
Mean ± Standard Deviation
  54.2  ± 6.6     51.7  ± 10.8     52.9  ± 9.1  
Gender  
[units: participants]
     
Female     09     14     23  
Male     08     05     13  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels   [ Time Frame: Baseline &12 Weeks ]

2.  Secondary:   Change in Flow-mediated Dilatation (FMD)   [ Time Frame: Baseline & 12 Weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Detection of changes in Oxidative stress with significance requires a much larger cohort study.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Arshed A Quyyumi, MD
Organization: Emory University
phone: 404 712 2741
e-mail: aquyyum@emory.edu


Publications of Results:

Responsible Party: Arshed A. Quyyumi, Emory University
ClinicalTrials.gov Identifier: NCT00166036     History of Changes
Other Study ID Numbers: 1038-2004
Study First Received: September 12, 2005
Results First Received: June 8, 2012
Last Updated: August 28, 2014
Health Authority: United States: Institutional Review Board